## SEQUENCE LISTING

```
<110> Sokoll, Kenneth K.
<120>
      Stabilized Synthetic Immunogen Delivery System
<130>
      Immunogen Delivery System
<160> 11
<170> PatentIn version 3.1
<210>
      7
<211>
      32
<212>
      DNA
<213>
      Artificial Sequence
<220>
<223> synthetic oligonucleotide
<400> 1
togtogtttt gtogttttgt ogttttgtog tt
<210>
<211> 25
<212>
      DNA
<213> Artificial Sequence
<220>
<223>
      synthetic oligonucleotide
<220>
<221>
      misc feature
<222>
      (1) ... (1)
<223> n indicates phosphorothicate group
<400> 2
ntcgtcgttt tgtcgttttg tcgtt
   25
<210>
      3
<211> 24
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223>
      synthetic oligonucleotide
<400> 3
togtogtttt gtogttttgt cgtt
<210>
<211>
       50
<212>
       PRT
<213>
       Human
<220>
<221>
       misc feature
<222>
      (20) ... (20)
<223>
      Xaa indicates epsilon-Lys
<400> 4
Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
                                     10
                                                         15
Ile Leu Phe Xaa Cys Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser
Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly
                            40
Asn Cys
    50
<210>
<211>
       50
<212>
       PRT
<213>
       Human
<220>
<221>
      misc feature
<222>
      (20)..(20)
<223> Xaa indicates epsilon-Lys
```

```
<400> 5
Lys Lys Lys Thr Asp Arg Val Ile Glu Val Leu Gln Arg Ala Gly Arg
Ala Ile Leu Xaa Cys Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser
                                 25
            20
Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly
                             40
                                                  45
Asn Cys
    50
<210>
       6
<211>
       31
<212>
       PRT
<213>
       Human
<220>
<221>
       misc feature
<222>
       (20)..(20)
<223>
       Xaa indicates epsilon-Lys
<400> 6
Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
                                     10
                                                          15
Ile Leu Phe Xaa Cys His Ala Ser Ile Tyr Asp Phe Gly Ser Cys
                                 25
            20
<210>
       7
<211>
       27
<212>
       PRT
<213>
```

Lvs Lvs Gln Tvr Ile Lvs Ala Asn Ser Lvs Phe Ile Gly Ile Thr Glu

Human

<400>

1.0 1.5 1 Leu Glu His Trp Ser Tyr Gly Leu Arg Pro Gly 20 <21.0> <211> 45 <212> PRT <213> Human <400> 8 Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gln Phe 1.0 15 Gly Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu 30 20 25 Glu Gly Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly 35 40 45 <210> <211> 45 <212> PRT <213> Human

<400> 9

Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gln Phe  $1 ext{ } 5 ext{ } 10 ext{ } 15$ 

Gly Gly Leu Ser Glu Ile Lys Gly Val Ile Val His Arg Leu Glu Gly 20 25 30

Val Gly Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly 35 40 45

<210> 10 <211> 44 <212> PRT

```
<213>
       Human
<220>
<221>
       misc_feature
<222>
       (19)..(19)
<223>
       Xaa indicates epsilon-Lys
<400> 10
Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile Thr Ile Ile Thr Thr
Ile Asp Xaa Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro His
Leu Pro Arq Ala Leu Met Arg Ser Thr Thr Lys Cys
                            40
<210>
       11
<211>
       45
<212>
       PRT
<213>
       Human
<220>
<221>
       misc feature
<222>
       (20) . . (20)
<223>
       Xaa indicates epsilon-Lys
<400> 11
Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
Ile Leu Phe Xaa Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro
            20
His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
        35
                            40
```